0	11	Comparative	comparative	JJ
12	20	analysis	analysis	NN
21	23	of	of	IN
24	28	NFAT	NFAT	NNP
29	30	(	(	(
30	37	nuclear	nuclear	JJ
38	44	factor	factor	NN
45	47	of	of	IN
48	57	activated	activate	VBN
58	59	T	t	NN
60	65	cells	cell	NNS
65	66	)	)	)
67	74	complex	complex	NN
75	77	in	in	IN
78	83	human	human	JJ
84	85	T	t	NN
86	89	and	and	CC
90	91	B	b	NN
92	103	lymphocytes	lymphocyte	NNS
103	104	.	.	.

106	113	Nuclear	nuclear	JJ
114	120	factor	factor	NN
121	123	of	of	IN
124	133	activated	activate	VBN
134	135	T	t	NN
136	141	cells	cell	NNS
142	143	(	(	(
143	147	NFAT	NFAT	NNP
147	148	)	)	)
149	151	is	be	VBZ
152	153	a	a	DT
154	169	transcriptional	transcriptional	JJ
170	179	activator	activator	NN
180	184	that	that	WDT
185	190	binds	bind	VBZ
191	193	to	to	TO
194	203	sequences	sequence	NNS
204	206	in	in	IN
207	210	the	the	DT
211	224	interleukin-2	interleukin-2	NN
225	226	(	(	(
226	230	IL-2	il-2	NN
230	231	)	)	)
232	240	promoter	promoter	NN
241	244	and	and	CC
245	247	is	be	VBZ
248	255	thought	think	VBN
256	258	to	to	TO
259	261	be	be	VB
262	269	largely	largely	RB
270	281	responsible	responsible	JJ
282	285	for	for	IN
286	289	the	the	DT
290	291	T	t	NN
292	305	cell-specific	cell-specific	JJ
306	318	inducibility	inducibility	NN
319	321	of	of	IN
322	326	IL-2	il-2	NN
327	337	expression	expression	NN
337	338	.	.	.

339	354	Electrophoretic	electrophoretic	JJ
355	363	mobility	mobility	NN
364	369	shift	shift	NN
370	376	assays	assay	NNS
377	378	(	(	(
378	382	EMSA	EMSA	NNP
382	383	)	)	)
384	390	showed	show	VBD
391	395	that	that	IN
396	404	specific	specific	JJ
405	409	NFAT	nfat	NN
410	417	binding	binding	NN
418	426	activity	activity	NN
427	432	could	could	MD
433	437	also	also	RB
438	440	be	be	VB
441	448	induced	induce	VBN
449	451	in	in	IN
452	457	human	human	JJ
458	459	B	B	NNP
460	465	cells	cell	NNS
465	466	.	.	.

467	470	The	the	DT
471	472	B	B	NNP
473	477	cell	cell	NN
478	482	NFAT	nfat	NN
483	490	complex	complex	NN
490	491	,	,	,
492	499	however	however	RB
499	500	,	,	,
501	504	was	be	VBD
505	508	not	not	RB
509	519	functional	functional	JJ
519	520	,	,	,
521	526	since	since	IN
527	529	it	it	PRP
530	536	failed	fail	VBD
537	539	to	to	TO
540	548	activate	activate	VB
549	562	transcription	transcription	NN
563	567	from	from	IN
568	570	an	an	DT
571	582	NFAT-driven	nfat-driven	JJ
583	598	chloramphenicol	chloramphenicol	NN
599	616	acetyltransferase	acetyltransferase	NN
617	618	(	(	(
618	621	CAT	CAT	NNP
621	622	)	)	)
623	632	construct	construct	NN
632	633	.	.	.

634	645	Competition	competition	NN
646	650	with	with	IN
651	653	an	an	DT
654	658	AP-1	ap-1	NN
659	664	motif	motif	NN
665	667	or	or	CC
668	672	with	with	IN
673	681	anti-Jun	anti-jun	JJ
682	685	and	and	CC
686	694	anti-Fos	anti-fos	JJ
695	705	antibodies	antibody	NNS
706	715	abolished	abolish	VBD
716	723	binding	binding	NN
724	726	to	to	TO
727	730	the	the	DT
731	735	NFAT	nfat	NN
736	741	motif	motif	NN
742	744	in	in	IN
745	749	both	both	CC
750	751	T	t	NN
752	755	and	and	CC
756	757	B	b	NN
758	763	cells	cell	NNS
763	764	,	,	,
765	775	indicating	indicate	VBG
776	780	that	that	IN
781	784	Jun	Jun	NNP
785	788	and	and	CC
789	792	Fos	Fos	NNP
793	796	are	be	VBP
797	805	critical	critical	JJ
806	809	for	for	IN
810	814	NFAT	NFAT	NNP
815	822	complex	complex	NN
823	832	formation	formation	NN
833	835	in	in	IN
836	840	both	both	DT
841	845	cell	cell	NN
846	851	types	type	NNS
851	852	.	.	.

853	861	Purified	purify	VBN
862	873	recombinant	recombinant	JJ
874	877	Jun	Jun	NNP
878	881	and	and	CC
882	885	Fos	Fos	NNP
886	894	proteins	protein	NNS
895	901	failed	fail	VBD
902	904	to	to	TO
905	909	bind	bind	VB
910	918	directly	directly	RB
919	921	to	to	TO
922	925	the	the	DT
926	930	NFAT	NFAT	NNP
931	936	motif	motif	NN
936	937	.	.	.

938	945	However	however	RB
945	946	,	,	,
947	951	when	when	WRB
952	960	combined	combine	VBN
961	965	with	with	IN
966	978	unstimulated	unstimulated	JJ
979	980	B	b	NN
981	983	or	or	CC
984	985	T	t	NN
986	990	cell	cell	NN
991	999	extracts	extract	NNS
999	1000	,	,	,
1001	1012	full-length	full-length	JJ
1012	1013	,	,	,
1014	1017	but	but	CC
1018	1021	not	not	RB
1022	1031	truncated	truncate	VBN
1031	1032	,	,	,
1033	1040	Jun/Fos	Jun/Fos	NNP
1041	1053	heterodimers	heterodimer	NNS
1054	1058	were	be	VBD
1059	1063	able	able	JJ
1064	1066	to	to	TO
1067	1071	form	form	VB
1072	1074	an	an	DT
1075	1079	NFAT	nfat	NN
1080	1087	complex	complex	NN
1087	1088	,	,	,
1089	1099	indicating	indicate	VBG
1100	1103	the	the	DT
1104	1112	presence	presence	NN
1113	1115	of	of	IN
1116	1117	a	a	DT
1118	1132	constitutively	constitutively	RB
1133	1142	expressed	express	VBN
1143	1150	nuclear	nuclear	JJ
1151	1160	factor(s)	factor(s)	NN
1161	1163	in	in	IN
1164	1165	B	B	NNP
1166	1169	and	and	CC
1170	1171	T	t	NN
1172	1177	cells	cell	NNS
1178	1187	necessary	necessary	JJ
1188	1191	for	for	IN
1192	1195	the	the	DT
1196	1205	formation	formation	NN
1206	1208	of	of	IN
1209	1212	the	the	DT
1213	1217	NFAT	NFAT	NNP
1218	1225	complex	complex	NN
1226	1228	in	in	IN
1229	1233	both	both	DT
1234	1238	cell	cell	NN
1239	1244	types	type	NNS
1244	1245	.	.	.

1246	1248	An	an	DT
1249	1253	NFAT	NFAT	NNP
1254	1269	oligonucleotide	oligonucleotide	NN
1270	1278	carrying	carry	VBG
1279	1288	mutations	mutation	NNS
1289	1291	in	in	IN
1292	1295	the	the	DT
1296	1297	5	5	CD
1297	1298	’	'	SYM
1299	1310	purine-rich	purine-rich	JJ
1311	1315	part	part	NN
1316	1318	of	of	IN
1319	1322	the	the	DT
1323	1327	NFAT	NFAT	NNP
1328	1336	sequence	sequence	NN
1337	1343	failed	fail	VBD
1344	1346	to	to	TO
1347	1351	form	form	VB
1352	1353	a	a	DT
1354	1361	complex	complex	NN
1362	1365	and	and	CC
1366	1368	to	to	TO
1369	1376	compete	compete	VB
1377	1381	with	with	IN
1382	1385	the	the	DT
1386	1390	wild	wild	JJ
1391	1395	type	type	NN
1396	1401	motif	motif	NN
1402	1405	for	for	IN
1406	1410	NFAT	NFAT	NNP
1411	1418	complex	complex	NN
1419	1428	formation	formation	NN
1429	1431	in	in	IN
1432	1436	both	both	CC
1437	1438	T	t	NN
1439	1442	and	and	CC
1443	1444	B	b	NN
1445	1450	cells	cell	NNS
1450	1451	.	.	.

1452	1454	We	we	PRP
1455	1464	therefore	therefore	RB
1465	1472	propose	propose	VBP
1473	1474	a	a	DT
1475	1480	model	model	NN
1481	1488	whereby	whereby	WRB
1489	1490	a	a	DT
1491	1495	core	core	NN
1496	1500	NFAT	nfat	NN
1501	1508	complex	complex	NN
1509	1519	consisting	consist	VBG
1520	1522	of	of	IN
1523	1526	Jun	Jun	NNP
1526	1527	,	,	,
1528	1531	Fos	Fos	NNP
1531	1532	,	,	,
1533	1536	and	and	CC
1537	1538	a	a	DT
1539	1551	constitutive	constitutive	JJ
1552	1559	nuclear	nuclear	JJ
1560	1566	factor	factor	NN
1567	1569	is	be	VBZ
1570	1576	formed	form	VBN
1577	1579	in	in	IN
1580	1584	both	both	CC
1585	1586	T	t	NN
1587	1590	and	and	CC
1591	1592	B	b	NN
1593	1598	cells	cell	NNS
1598	1599	,	,	,
1600	1603	but	but	CC
1604	1606	an	an	DT
1607	1617	additional	additional	JJ
1618	1624	factor	factor	NN
1625	1631	and/or	and/or	CC
1632	1650	post-translational	post-translational	JJ
1651	1663	modification	modification	NN
1664	1666	of	of	IN
1667	1668	a	a	DT
1669	1675	factor	factor	NN
1675	1676	,	,	,
1677	1684	missing	miss	VBG
1685	1687	in	in	IN
1688	1689	B	B	NNP
1690	1695	cells	cell	NNS
1695	1696	,	,	,
1697	1702	might	might	MD
1703	1705	be	be	VB
1706	1714	required	require	VBN
1715	1718	for	for	IN
1719	1734	transactivation	transactivation	NN
1735	1737	by	by	IN
1738	1742	NFAT	NFAT	NNP
1742	1743	.	.	.